Lumito Advances Automated Pathology with Promising SCIZYS Platform Integration

Swedish biotech company Lumito, based in Lund, has made significant progress in automating immunohistochemistry (IHC) pathology processes through its innovative SCIZYS platform. This platform utilizes upconverting nanoparticles to enhance IHC by providing higher sensitivity, a broader signal range, and quantitative data compared to traditional methods.

To facilitate widespread adoption in pathology labs, Lumito focused on integrating SCIZYS with existing automated staining instruments. Through a collaboration with Offspring Biosciences, Lumito adapted its manual SCIZYS Erbium analysis for the automated Discovery Ultra IHC platform. A recent pilot study was conducted, involving reagent kits supplied by Lumito and scanning of stained tissue samples jointly evaluated by both companies.

The initial results from this pilot are promising, indicating that the SCIZYS Erbium kit can be successfully incorporated into the Discovery Ultra system with only minor protocol adjustments. While further optimization is planned, this development marks a significant step toward making high-sensitivity IHC available on automated platforms widely used in pathology labs. Importantly, the partnership carries no financial or commercial obligations beyond pilot study execution and evaluation.

This progress positions Lumito’s technology to potentially transform automated pathology by enhancing diagnostic accuracy and efficiency through quantitative and sensitive tissue analysis.